17 November 2022 - Brukinsa is the only Bruton’s tyrosine kinase inhibitor to achieve superiority over ibrutinib in relapsed/refractory chronic lymphocytic leukaemia.
BeiGene today announced that the European Commission has approved Brukinsa (zanubrutinib) for the treatment of adult patients with treatment naïve or relapsed/refractory chronic lymphocytic leukaemia.